$11.95
-0.51-4.09%
Last update: Nov 11, 7:25 PM
AbCellera Biologics Inc
ABCLNASDAQ
AbCellera Biologics rose 198.0% from $4.01 to $11.95, ahead of the S&P 500's +11.2%. Its worst day was Feb 5 (−15.0%), and its low came Feb 5 at $2.78.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
AbCellera Biologics shares rose 13.7%, while the S&P 500 rose 0.6%.
+13.7% · S&P 500 +0.6%
AbCellera Biologics closed at its lowest level of the year, 30.7% below where the year started.
−15.0%, the year's worst day · S&P 500 −1.2%
Story events cover the past 12 months · Times ET
EPS of $-0.03 beat the $-0.18 estimate on $44.9M revenue (est. $6.7M).
−0.9% · S&P 500 +0.8%
EPS of $-0.14 beat the $-0.20 estimate on $8.3M revenue (est. $5.7M).
−5.7% · S&P 500 −0.2%
EPS of $-0.18 missed the $-0.17 estimate on $4.0M revenue (est. $7.8M).
+10.3% · S&P 500 −0.2%
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
+17.8% · S&P 500 +0.3%
AbCellera Biologics closed at its highest level of the year, 269.6% above where the year started.
+6.5% · S&P 500 −0.2%
EPS of $-0.13 beat the $-0.18 estimate on $10.6M revenue (est. $6.1M).
−0.3% · S&P 500 −0.4%
Where it ended: a close of $11.95 on Nov 11, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-0.17, revenue est. $7.0M).
Nothing in the past 12 months.
All ABCL dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ABCL and SPY from Benzinga historical bars. Not investment advice.
